Genmab — Marts 2017
-
-
In our view, this is potentially game-changing data and even though it has to be confirmed in real clinical settings and the ongoing in-human clinical trials, it bodes well for the potential combination effect of Darzalex with PD1 and PD-L1 therapy in solid tumours, particularly for lung cancer, based on these results. As already mentioned, we do not yet include sales and valuation for Darzalex in solid tumours in our model but have previously concluded that it could add up to USD 5bn (or more)
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind